Background:Dermatophagoides pteronyssinus is one of the most important perennial allergen sources worldwide. Molecular diagnostics using the commercially available major allergens (Der p 1 and Der p 2) in combination with Der p 10 do not detect house dust mite (HDM) sensitization in a number of cases when used alone. The objective was to evaluate the IgE reactivity profiles of these patients using an experimental immunoassay biochip. Methods: Sera of HDM-allergic patients (positive skin prick test, CAP class ≥1 for allergen extract, and positive intranasal provocation) were tested for IgE antibodies against Der p 1, Der p 2, and Der p 10 by ImmunoCAP fluorescence enzyme immunoassay. Negatively tested sera were examined by an experimental chip containing 13 microarrayed HDM allergens. Results: Of 97 patients tested, 16 showed negative results to Der p 1, Der p 2, and Der p 10. MeDALL chip evaluation revealed 5 patients monosensitized to Der p 23, and 11 patients were negative for all HDM MeDALL chip components. Seven sera were available for further testing, and 3 of them showed IgE reactivity to dot-blotted nDer p 1, and 2 reacted with high-molecular weight components (>100 kDa) in nitrocellulose-blotted HDM extract when tested with 125I-labeled anti-IgE in a RAST-based assay. The HDM extract-specific IgE levels of the 11 patients were <3.9 kU/l. Conclusions: Recombinant allergen-based IgE serology is of great value when conventional IgE diagnostics fails. Der p 23 is an important HDM allergen, especially when major allergens are negative. Therefore, it would be desirable to have Der p 23 commercially available. Further research concerning the prevalence and clinical significance of different HDM allergens is needed.

Keywords:
Major allergens, Allergen components, Allergic rhinitis, Der p 1, Der p 2, Der p 23, Dermatophagoides pteronyssinus, House dust mites
1.
Bousquet J, Lockey R, Malling HJ, Alvarez-Cuesta E, Canonica GW, Chapman MD, et al: Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American Academy of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1998;81:401-405.
2.
Pittner G, Vrtala S, Thomas WR, Weghofer M, Kundi M, Horak F, et al: Component-resolved diagnosis of house-dust mite allergy with purified natural and recombinant mite allergens. Clin Exp Allergy 2004;34:597-603.
3.
Westritschnig K, Sibanda E, Thomas W, Auer H, Aspock H, Pittner G, et al: Analysis of the sensitization profile towards allergens in central Africa. Clin Exp Allergy 2003;33:22-27.
4.
Becker S, Kramer MF, Havel M, Welz C, Markmann S, Groger M: IgE reactivity profiles among house dust mite allergic patients in Bavaria. Eur Arch Otorhinolaryngol 2013;270:3177-3182.
5.
Weghofer M, Thomas WR, Kronqvist M, Mari A, Purohit A, Pauli G, et al: Variability of IgE reactivity profiles among European mite allergic patients. Eur J Clin Invest 2008;38:959-965.
6.
Becker S, Groger M, Canis M, Pfrogner E, Kramer MF: Tropomyosin sensitization in house dust mite allergic patients. Eur Arch Otorhinolaryngol 2012;269:1291-1296.
7.
Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S: Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007;1:CD001936.
8.
Nelson HS: Update on house dust mite immunotherapy: are more studies needed? Curr Opin Allergy Clin Immunol 2014;14:542-548.
9.
Calderon MA, Casale TB, Nelson HS, Demoly P: An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies. J Allergy Clin Immunol 2013;132:1322-1336.
10.
Meyer CH, Bond JF, Chen MS, Kasaian MT: Comparison of the levels of the major allergens Der p I and Der p II in standardized extracts of the house dust mite, Dermatophagoides pteronyssinus. Clin Exp Allergy 1994;24:1041-1048.
11.
Weghofer M, Grote M, Resch Y, Casset A, Kneidinger M, Kopec J, et al: Identification of Der p 23, a peritrophin-like protein, as a new major Dermatophagoides pteronyssinus allergen associated with the peritrophic matrix of mite fecal pellets. J Immunol 2013;190:3059-3067.
12.
Lupinek C, Wollmann E, Baar A, Banerjee S, Breiteneder H, Broecker BM, et al: Advances in allergen-microarray technology for diagnosis and monitoring of allergy: the MeDALL allergen-chip. Methods 2014;66:106-119.
13.
Riechelmann H, Bachert C, Goldschmidt O, Hauswald B, Klimek L, Schlenter WW, et al: Application of the nasal provocation test on diseases of the upper airways. Position paper of the German Society for Allergology and Clinical Immunology (ENT Section) in cooperation with the Working Team for Clinical Immunology (in German). Laryngorhinootologie 2003;82:183-188.
14.
Bronnert M, Mancini J, Birnbaum J, Agabriel C, Liabeuf V, Porri F, et al: Component-resolved diagnosis with commercially available D. pteronyssinus der p 1, der p 2, and der p 10: relevant markers for house dust mite allergy. Clin Exp Allergy 2012;42:1406-1415.
15.
Thomas WR, Smith WA, Hales BJ, Mills KL, O'Brien RM: Characterization and immunobiology of house dust mite allergens. Int Arch Allergy Immunol 2002;129:1-18.
16.
Thomas WR, Smith WA, Hales BJ: The allergenic specificities of the house dust mite. Chang Gung Med J 2004;27:563-569.
17.
Trombone AP, Tobias KR, Ferriani VP, Schuurman J, Aalberse RC, Smith AM, et al: Use of a chimeric ELISA to investigate immunoglobulin E antibody responses to Der p 1 and Der p 2 in mite-allergic patients with asthma, wheezing and/or rhinitis. Clin Exp Allergy 2002;32:1323-1328.
18.
Soh WT, Le Mignon M, Suratannon N, Satitsuksanoa P, Chatchatee P, Wongpiyaboron J, et al: The house dust mite major allergen Der p 23 displays O-glycan-independent IgE reactivities but no chitin-binding activity. Int Arch Allergy Immunol 2016;168:150-160.
19.
Hales BJ, Laing IA, Pearce LJ, Hazell LA, Mills KL, Chua KY et al: Distinctive immunoglobulin E anti-house dust allergen-binding specificities in a tropical Australian Aboriginal community. Clin Exp Allergy 2007;37:1357-1363.
20.
Yasueda H, Mita H, Yui Y, Shida T: Comparative analysis of physicochemical and immunochemical properties of the two major allergens from Dermatophagoides pteronyssinus and the corresponding allergens from Dermatophagoides farinae. Int Arch Allergy Appl Immunol 1989;88:402-407.
21.
Chan TF, Ji KM, Yim AK, Liu XY, Zhou JW, Li RQ, et al: The draft genome, transcriptome, and microbiome of Dermatophagoidesfarinae reveal a broad spectrum of dust mite allergens. J Allergy Clin Immunol 2015;135:539-548.
22.
Malandain H: IgE-reactive carbohydrate epitopes - classification, cross-reactivity, and clinical impact (2nd part). Eur Ann Allergy Clin Immunol 2005;37:247-256.
23.
van Ree R: Carbohydrate epitopes and their relevance for the diagnosis and treatment of allergic diseases. Int Arch Allergy Immunol 2002;129:189-197.
24.
Altmann F: The role of protein glycosylation in allergy. Int Arch Allergy Immunol 2007;142:99-115.
25.
Vidal C, Sanmartin C, Armisen M, Rodriguez V, Linneberg A, Gonzalez-Quintela A: Minor interference of cross-reactive carbohydrates with the diagnosis of respiratory allergy in standard clinical conditions. Int Arch Allergy Immunol 2012;157:176-185.
26.
Malandain H, Giroux F, Cano Y: The influence of carbohydrate structures present in common allergen sources on specific IgE results. Eur Ann Allergy Clin Immunol 2007;39:216-220.
27.
Casset A, Mari A, Purohit A, Resch Y, Weghofer M, Ferrara R, et al: Varying allergen composition and content affects the in vivo allergenic activity of commercial Dermatophagoides pteronyssinus extracts. Int Arch Allergy Immunol 2012;159:253-262.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.